Drug-eluting stent, but not bare metal stent, accentuates the systematic inflammatory response in patients

Cardiology. 2014;128(3):259-65. doi: 10.1159/000358508. Epub 2014 May 16.

Abstract

Objective: The systematic pro-inflammatory responses after percutaneous coronary intervention with drug-eluting stents (DES) remain poorly defined. Therefore, we compared the systematic pro-inflammatory state of circulating mononuclear cells (MNCs) between DES and bare metal stent (BMS) implantation.

Methods: Patients with indications for treatment with stents were randomized in a 1:1 ratio to placement of DES or BMS. The primary endpoint was a change of pro-inflammatory state at 12 weeks post-procedure.

Results: Thirty-six consecutive patients received DES or BMS. At 12 weeks after stent implantation, the lipid profile and high-sensitivity C-reactive protein (hs-CRP) improved significantly in both groups. The mRNA levels and plasma concentrations of interleukin-6, tumor necrosis factor-α and matrix metalloproteinase-9 were significantly elevated in the DES group, which was not observed in the BMS group. An increase in NF-κB binding activity and a decrease in PPAR-γ expression in MNCs were observed in the DES group, along with increases in IκB phosphorylation and p50 expression. However, similar changes were not observed in the BMS group.

Conclusions: Systematic inflammatory responses were accentuated after the patients were treated percutaneously with DES, despite their improved lipid profile and hs-CRP. These data may provide fundamental information for optimizing therapeutic strategy in the era of DES.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • C-Reactive Protein / metabolism
  • Coronary Stenosis / therapy
  • Drug-Eluting Stents / adverse effects
  • Enzyme-Linked Immunosorbent Assay
  • Everolimus
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Interleukin-4 / metabolism
  • Interleukin-6 / metabolism
  • Leukocytes, Mononuclear / metabolism
  • Matrix Metalloproteinase 9 / metabolism
  • RNA, Messenger / metabolism
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives
  • Stents / adverse effects*
  • Systemic Inflammatory Response Syndrome / etiology*
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Immunosuppressive Agents
  • Interleukin-6
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • Interleukin-4
  • C-Reactive Protein
  • Everolimus
  • Matrix Metalloproteinase 9
  • Sirolimus